MDMA-assisted therapy

As the U.S. celebrates Veterans Day, more and more war vets are seeking alternative treatments for post-traumatic stress disorder (PTSD) in the hope of finding relief. Among the most promising therapies is psychedelic-assisted therapy, which has demonstrated significant potential in helping...

Federal agencies recently convened in a pivotal public meeting, hosted by the Reagan-Udall Foundation for the U.S. Food and Drug Administration (FDA), to discuss emerging treatments for post-traumatic stress disorder (PTSD), with a focus on the potential of psychedelics. As Lexology reported, the...

The Department of Veterans Affairs (VA) is signaling potential support for another pivotal Phase III clinical trial of psychedelic therapy to treat post-traumatic stress disorder (PTSD). As Politico reported, Dr. Shereef Elnahal, the undersecretary for health at the VA, revealed that the agency is...

PharmAla Biotech Holdings Inc. (OTC:MDXXF) has announced that it will supply its Good Manufacturing Practice LaNeo MDMA for a clinical trial at Mt. Sinai Health System. The biotechnology company specializes in the research, development, and production of MDMA and novel MDXX-class molecules. "We're...

PharmAla Biotech Holdings Inc. (OTC:MDXXF), a Canadian company specializing in MDMA research and development, announced its selection as a supplier for a clinical trial at the University of Texas, San Antonio. The trial will focus on testing a novel dosage form of PharmAla's proprietary LaNeo MDMA...

Sam Altman, co-founder of OpenAI and the visionary behind ChatGPT, recently opened up about his transformative experiences with psychedelics in his appearance on the podcast Life in Seven Songs. The tech executive shared personal anecdotes about how psychedelic experiences profoundly impacted his...

The U.S. Food and Drug Administration (FDA) has issued a complete response letter for MDMA-assisted psychotherapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) in which it calls for an additional phase 3 trial to further evaluate its safety and efficacy. As Psychiatric Times...

The Multidisciplinary Association for Psychedelic Studies (MAPS) is pivoting its focus to state-level initiatives following the U.S. Food and Drug Administration's (FDA) recent denial of MDMA-assisted therapy. As recently reported by Double Blind, MAPS gathered a panel of experts to discuss what...

Drug Science and University College London (UCL) announced a strategic partnership to advance research into MDMA-assisted psychotherapy. This collaboration aims to refine our understanding of how MDMA works in conjunction with psychotherapeutic treatments, addressing concerns that the "...

Less than a month after the FDA rejected MDMA for PTSD treatment, and days after the agency set a September meeting to discuss psychedelic and other treatments for PTSD, the Multidisciplinary Association for Psychedelic Studies (MAPS) awarded a $200,000 grant to Emory University researchers for a...

Lykos Therapeutics has announced a strategic reorganization in response to the recent FDA decision regarding its new drug application for MDMA capsules – also known as Ecstasy or Molly – intended for treating post-traumatic stress disorder (PTSD) in adults. New Senior Medical Advisor As...

In a significant development in the field of psychedelic medicine, the journal Psychopharmacology has retracted three research papers on MDMA-assisted therapy due to what it described as unethical conduct at one of the study sites. As New York Times reported, the retraction has cast a shadow over...

The potential of MDMA-assisted therapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) has garnered significant attention, including many scientific studies that indicate promising results. However, while the majority of the results suggest safety and efficacy, researchers emphasize...

Close to the White House in Lafayette Park, 17 pairs of Army boots form a solemn row. These boots represent a tragic statistic from the U.S. Department of Veterans Affairs: every day an average of at least 17 military veterans die by suicide. Advocacy Groups Urge FDA To Approve Psychedelic Therapy...

Two separate deals hit the wires on Tuesday. One is PharmAla Biotech's (OTC:MDXXF) with Numinus Wellness (OTC:NUMIF) for a group therapy model with MDMA, the other is Optimi Health's (OTCQX:OPTHF) with Tel Aviv University for MDMA’s potential effects on addiction treatment. PharmAla Signs...